Buprenorphine is the exception to mandatory reductions and decreased opioid prescribing, with dramatically increasing numbers of people being treated for both chronic pain and opioid use disorder with additional national emphasis on expanding practice to meet treatment needs. Even with expanding prescribing limits and extending prescribing to mid-level providers, the management of buprenorphine products is intensive and requires a team approach. In this session, we outline the integration of clinical pharmacy pain practitioners into a buprenorphine clinic to provide collaborative drug therapy management for patients with comorbid pain and opioid use disorder. Specializing in medication therapy management allows pharmacists to improve adherence to medication for opioid use disorder (MOUD), improve non-opioid pharmacotherapeutic approaches, and connect patients with all available services for pain. Pain pharmacy aligns well with the rigorous follow-up schedule and monitoring parameters necessary for successful engagement and retention in this population, thereby improving outcomes and decompressing physician partners. We will present data on several years of clinic implementation from pilot to practice with impressive outcomes including increased engagement, retention, and decreased mortality.